View clinical trials related to Osteoarthritis.
Filter by:The USAGE study aims at assessing on a long-term period (two years in average) the outcome in clinical or economical term of patients with knee osteoarthritis (OA) treated or not with Synvisc®, in the 1139.4 clinical trial.
Retrospective collection of data, aimed at a better knowledge of the context of use of Synvisc® among the patients practising a regular activity (professional/leisure), and at evaluating the different practices and their results.
The current clinical trial is designed to test the analgesic and anti-inflammatory efficacy of a topical cream compared to a placebo cream. The study population will be those with mild to moderate osteoarthritis of the knee. The trial will also provide information about potential side effects and verify the safety of this composition. Blood levels will be done to assess inflammation and to determine whether any systemic absorption has occurred. Hypothesis/Purpose - Pain scores after active treatment will be significantly reduced in comparison to placebo. - There will be an improvement in stiffness and physical function as measured by the WOMAC using the active cream as compared to placebo. - There will be a decrease in the level of inflammation assessed at baseline, end of week 3 and end of week 6. - The blood concentration of the active ingredient in the topical cream will not exceed the maximum daily dose that will be consumed by participants.
This is a Phase I, prospective, active-controlled, randomized, open-label, clinical trial designed to assess the safety and tolerability of single intra-articular injection of RegenoGel-SP for the treatment of OA. RegenoGel-SP is composed of fibrinogen in plasma linked to a high molecular weight HA. The viscoelastic properties resulting from the combination of these two natural macromolecules is further enhanced by joint surface associated factors to generate a viscoelastic gel with superior stability and mechanical integrity.
Phase 1 will evaluate the safety of 3 intra-articular injections of Ampion™ administered 2 weeks apart to adults with osteoarthritis of the knee. In the absence of serious drug-related Adverse Events (AEs) of unanticipated drug-related AEs, enrollment will be initiated in Phase 2 of the study. Phase 2 will evaluate the efficacy of 3 intra-articular injections, given 2 weeks apart, of Ampion™ in Adults with pain due to osteoarthritis of the knee.
Study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases.
To assess the efficacy and safety of meloxicam 7.5mg once daily compared with diclofenac 100mg SR once daily over a treatment period of 8 weeks
To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days
Study to compare the percentage of treatment successes or failures in patients randomized to meloxicam 7.5 mg vs. usual care prescription NSAIDs. Additionally, health care utilization, efficacy and safety of patients in a managed healthcare setting with osteoarthritis (OA) of the hip, knee, hand or spine will be assessed.
The aim of the study is to investigate - the indication for MOBEC in a dose of 15 mg per day - the treatments patients were receiving before switching to 15 mg MOBEC - how treatment with 15 mg is assessed compared with previous treatment - how effective and safe treatment with 15 mg MOBEC is considered